ER induces an increase of cell proliferation and of cancer progression, decreases apoptosis, transactivates the expression of many proteins like progesterone receptor (used as a marker of ER activity), and can activate different pathways [mitogen-activated protein kinase (MAPK), proto-oncogene tyrosine-protein kinase Src (Src), phosphatidylinositol 3-kinase (PI3K)] [13, 14]. Here, SRC is linked to cancer.